Learn about enhanced risk stratification criteria for GIST, including tumor size, mitotic index, and tumor site.1
Learn More
An integrated multidisciplinary approach can best evaluate the growing body of data, updated consensus guidelines and changing standards of patient care for the treatment of GIST.2
Learn More
GISTA are relatively uncommon, so differential diagnosis can be complicated. KIT staining provides important information that can help confirm a diagnosis.2
Learn More
The treatment for GIST depends on a number of factors including the patient's general health and the size and site of the tumors.
Learn More
What is GIST ALLIANCE?
Novartis, the global leader in KIT+ GIST therapy, has been working with healthcare professionals and patients worldwide to help improve the treatment of KIT+ GIST. GIST ALLIANCE™, is a unique support program designed to help optimize outcomes in KIT+ GIST patients.
